Regeneus is aiming to sign one or more clinical development licence deals for Progenza in the current financial year. It is well placed to achieve this goal, having already granted AGC an exclusive licence to manufacture Progenza for Japan, reported promising signs of efficacy from the successful Phase I trial of Progenza in knee osteoarthritis and been granted a Progenza patent in Japan. Regeneus reported an A$3.3m profit in FY17, thanks to the US$5.5m upfront payment and US$1m milestone fro
07 Sep 2017
Preparing for a clinical licence deal in Japan
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Preparing for a clinical licence deal in Japan
Cambium Bio Ltd (CMB:ASX) | 0 0 -7.7% | Mkt Cap: 25.1m
- Published:
07 Sep 2017 -
Author:
Dr Dennis Hulme -
Pages:
9
Regeneus is aiming to sign one or more clinical development licence deals for Progenza in the current financial year. It is well placed to achieve this goal, having already granted AGC an exclusive licence to manufacture Progenza for Japan, reported promising signs of efficacy from the successful Phase I trial of Progenza in knee osteoarthritis and been granted a Progenza patent in Japan. Regeneus reported an A$3.3m profit in FY17, thanks to the US$5.5m upfront payment and US$1m milestone fro